Author

Ana Carolina Ferreira Cardoso

Observed names: Ana Carolina Cardoso, Cardoso, Ana Carolina Ferreira

Institution: Libbs (Brazil)

Observed institutions: The University of Texas MD Anderson Cancer Center, Universidade Federal de São Carlos, Universidade de São Paulo, Instituto do Câncer do Estado de São Paulo, Libbs (Brazil), Clinics Hospital of Ribeirão Preto

ORCID: 0000-0002-9612-2285

Observed ORCID: 0000-0002-9612-2285

OpenAlex ID: A5005326550

Galectin-3 Determines Tumor Cell Adaptive Strategies in Stressed Tumor Microenvironments

2016 · Ana Carolina Ferreira Cardoso, Luciana Nogueira de Sousa Andrade, et al. · Frontiers in Oncology · 102

Exercise during preoperative therapy increases tumor vascularity in pancreatic tumor patients

2019 · Claudia Alvarez Florez Bedoya, Ana Carolina Ferreira Cardoso, et al. · Scientific Reports · 86

Recombinant disintegrin domain of human ADAM9 inhibits migration and invasion of DU145 prostate tumor cells

2015 · Ana Carolina Baptista Moreno Martin, Ana Carolina Ferreira Cardoso, et al. · Cell Adhesion & Migration · 17

Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population

2024 · Debora Gagliato, Tomás Reinert, et al. · Oncology and Therapy · 6

Knowledge, Use, and Perception of Brazilian Women about Contraceptive Methods: An Observational Study

2024 · Juliana Dineia Perez Brandão, Rogerio Bonassi Machado, et al. · Women s Health Reports · 5

Retrospective Observational Study of the Long-Term Safety and Efficacy Outcomes of Rituximab Biosimilar: Partial Data of RTXM83-AC-01-11 Subanalysis Study

2022 · Jessika Bridi, Ana Carolina Ferreira Cardoso, et al. · Blood · 2

Long-Term Safety and Effectiveness of Rituximab Biosimilar RTXM83: A Retrospective Extension Study in Brazilian Patients with Diffuse Large B-Cell Lymphoma

2024 · Marcia Torresan Delamain, Ana Carolina Ferreira Cardoso, et al. · Oncology and Therapy · 1

A prospective real-world study to assess the effectiveness and safety of trastuzumab biosimilar in the adjuvant treatment of HER2-positive breast cancer: Preliminary safety results.

2023 · Ana Carolina Ferreira Cardoso, Debora De Melo Gagliato, et al. · Journal of Clinical Oncology · 1

Doença de Chagas: uma abordagem educativa

2024 · Cardoso, Ana Carolina Ferreira, Carneiro, Bruna Emanuela Rodrigues, et al. · Arca - Repositório Institucional da Fiocruz

A prospective real-world study to assess the effectiveness and safety of trastuzumab biosimilar in the adjuvant treatment of HER2-positive breast cancer: Preliminary safety results.

2022 · Ana Carolina Ferreira Cardoso, Debora De Melo Gagliato, et al. · Journal of Clinical Oncology

Double-binding and Effector Activity of Trastuzumab-dkst Biosimilar Compared to Originator Trastuzumab in Combination With Pertuzumab in Her2-positive Breast Cancer Cell Lines

2021 · Franklin Fernandes Pimentel, Daniel Guimarães Tiezzi, et al. · Brazilian Journal of Oncology

Synergistic Mechanisms of Action: Comparison of Adcc and Signaling Pathways Inhibition by Trastuzumab Biosimilar or Originator Trastuzumab in Combination With Pertuzumab in Her2+ Breast Cancer Cell Lines

2021 · Franklin Fernandes Pimentel, Daniel Guimarães Tiezzi, et al. · Mastology

A Prospective Real-world National Study to Evaluate the Efficacy and Safety of Adjuvant Biosimilar Trastuzumab in the Treatment of Her2-positive Breast Cancer

2019 · Vivienne Castilho, Ana Carolina Ferreira Cardoso, et al. · Brazilian Journal of Oncology

Consequências da exposição de células de melanoma ao shear stress para o remodelamento da microvasculatura intratumoral

2019 · Ana Carolina Ferreira Cardoso · Digital Library of Theses and Dissertations (Universidade de São Paulo)

Modulação da expressão de galectina-3 frente às pressões seletivas de pH e oxigenação: um mecanismo para a heterogeneidade intratumoral?

2014 · Ana Carolina Ferreira Cardoso · Digital Library of Theses and Dissertations (Universidade de São Paulo)

Works count: 15

Citation count: 220

H-index: 5

I10-index: 3